GlobeNewswire

Clariant acquires remaining 70% in Brazilian Personal Care specialty company Beraca to seize full control

Share

Clariant acquires remaining 70% in Brazilian Personal Care specialty company Beraca to seize full control

  • Personal Care business strengthened by assuming full operational ownership of Beraca’s broad portfolio of natural ingredients, supporting growing customer demand for sustainable and ethically sourced materials
  • Clariant to build on Beraca’s outstanding expertise in natural and organic certified ingredients sustainably drawn from Brazil’s biodiversity
  • Clariant to continue Beraca's contributions to Brazilian social and economic development of local communities


Muttenz/São Paulo, August 23, 2021 – Clariant, a focused, sustainable and innovative specialty chemicals company, has signed an agreement to acquire the remaining 70% in Brazilian Personal Care Specialties company Beraca from the founding Sabará family. Clariant has held a 30% stake in the company since 2015. The purchase price will not be disclosed. The acquisition is subject to regulatory approvals and is expected to close in Q4 2021.

Beraca is one of the key manufacturers of natural ingredients for the personal care sector offering inter alia fats, oils and botanicals, which are all collected and extracted in an environmentally sustainable production process. Located in the Amazon region, Beraca promotes the development of communities, making them part of the Personal Care business on a global scale while simultaneously being strongly committed to sustainability and fair trade processes. In more than 30 years since its foundation, Beraca has received several awards and recognition from customers and institutions as a leading company in ethical sourcing aspects for Personal Care ingredients. Since 2015, Beraca has invested significant resources in expanding research and innovation and has steadily increased production capacity. With around 90 employees, the family-run company generated sales of USD 15 million in 2020.

“With its focus on sustainable products and processes, Beraca fits perfectly into Clariant's portfolio,” emphasizes Conrad Keijzer, CEO of Clariant. “We gain valuable access to natural materials based on the biodiversity of the Brazilian rainforest. This opens up great opportunities for high-quality growth for our Care Chemicals business.” 

“There is an increasing demand for ethically produced products on the world market, which we can meet even better with this acquisition,” says Christian Vang, Head of Business Unit Industrial & Consumer Specialties. He welcomes the Beraca team: “The excellent and highly creative team has written an extraordinary success story over the past five years, which we now want to continue and further develop under the Clariant umbrella.”

The acquisition of the remaining 70% in Beraca is a relevant building block in the strategy of further strengthening individual core business areas through targeted acquisitions. Beraca’s business will be integrated into the Care Chemicals Business Area.

CORPORATE MEDIA RELATIONSINVESTOR RELATIONS
Jochen Dubiel

Phone +41 61 469 63 63
jochen.dubiel@clariant.com
andreas schwarzwälder

Phone +41 61 469 63 73
andreas.schwarzwaelder@clariant.com
Claudia Kamensky

Phone +41 61 469 63 63
claudia.kamensky@clariant.com
Maria Ivek

Phone +41 61 469 63 73
maria.ivek@clariant.com
Alexander Kamb

Phone +41 61 469 63 73
alexander.kamb@clariant.com
Follow us on Twitter, Facebook, LinkedIn, Instagram.


This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.
www.clariant.com

Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2020, the company employed a total workforce of 13 235. In the financial year 2020, Clariant recorded sales of CHF 3.860 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer19.9.2021 13:30:00 CEST | Press release

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting2 Kisqali plus letrozole achieved median OS of over five years (63.9 months), a survival benefit of over 12 months vs. placebo plus letrozole in postmenopausal women (HR=0.76; p=0.004)2 Kisqali is the only CDK4/6 inhibitor with proven OS benefit across all three Phase III trials of the MONALEESA program with different endocrine therapy partners, regardless of menopausal status or line of therapy2-4 MONALEESA-2 OS data to be presented at ESMO Congress 2021 as a late-breaker in an oral session The digital press release with multimedia content can be accessed here: Basel, September 19, 2021 — Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combinati

Hypefactors announces launch of 4th generation Reputation AI18.9.2021 10:37:51 CEST | Press release

Copenhagen, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Announcement no. 13-2021 Inside Information Copenhagen, 18. September 2021 The SaaS company Hypefactors, that delivers a unified solution for media intelligence and reputation tracking, will launch its next generation Reputation AI (artificial intelligence) on September 20, 2021. Through algorithmic advances in machine learning, as well as drastically increased data curated by a team of in-house recruited linguists with diverse language and cultural backgrounds, Hypefactors incorporates the latest scientific advances in natural language processing to deliver unprecedented accuracy, precision and automation to commercial end-users. AI-assisted reputation tracking is a core feature of Hypefactors and enables large scale tracking from social media, news websites, tv, radio and reviews across the world. These real-time reputation insights can reveal early-stage opportunities (e.g. GameStop media hype), and/or defensively as an on-going protect

Repurchase of shares in Millicom17.9.2021 23:00:00 CEST | Press release

Repurchase of shares in Millicom Luxembourg, September17, 2021 - During the period September 9, 2021 – September 15, 2021, Millicom repurchased a total of 131,559 of its Swedish Depository Receipts (SDRs), hereinafter referred to as shares within the framework of the repurchase program announced on July 29, 2021, details of which are shown in the table below. DateNumber of shares repurchasedWeighted average repurchaseprice (SEK) excluding commissionsTotal daily transaction value (SEK), excluding commissions 09/09/2021 15,000 322.6863 4,840,294.50 10/09/2021 30,000 322.1097 9,663,291.00 13/09/2021 17,974 322.3942 5,794,713.35 14/09/2021 15,725 321.5394 5,056,207.07 15/09/2021 52,860 314.4509 16,621,874.57 All purchases were carried out on Nasdaq Stockholm by Citigroup Global Markets Limited on behalf of Millicom. Following the purchases, as of September 15, 2021, Millicom holds 792,425 treasury shares. The total number of shares outstanding in Millicom is 101,739,217. The repurchase pro

Palette Life Sciences lanserar ny varumärkeswebbplats med USA:s portfölj17.9.2021 18:09:14 CEST | Pressemelding

Varumärkesuppdatering för USA och globala kommersiella produkter för behandling av ouppfyllda medicinska behov SANTA BARBARA, Kalifornien och STOCKHOLM, Sverige, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Palette Life Sciences, ett helt integrerat globalt företag inom biovetenskap som arbetar för att förbättra patientutfall, lanserade idag sin nyligen uppdaterade webbplats Palettelifesciences.com. Webbplatsen har ett uppdaterat företagsvarumärke som stöder alla produkter i Palette Life Sciences-portföljen, och som fokuserar på minimalt invasiva behandlingar inriktade på ouppfyllda medicinska behov vid strålbehandling och interventionella onkologiska ingrepp, urologiska/urogynekologiska sjukdomar och kolorektala tillstånd. ”Vi inom Palette är stolta över vår förstklassiga produktportfölj som ger hopp åt dem med ouppfyllda medicinska behov”, säger Per G. Langö, Chief Executive Officer och Board Director för Palette Life Sciences. ”När vi bytte varumärke på vår webbplats övervägde vi hur vi bäst

Prosafe SE: bp charters Safe Zephyrus in 202217.9.2021 17:40:15 CEST | Press release

BP Exploration Operating Company Limited ('bp') has chartered the Safe Zephyrus to provide gangway connected operations to support the Seagull project at the ETAP central processing facility in the UK North Sea. The firm duration of the contract, starting Q1 2022, is 10 months with up to four months of options. The Safe Zephyrus is one of the world's most advanced and versatile accommodation vessels, complying with stringent rules in both UK and Norway and with a strong focus on reducing emissions by optimising the engine load. The value of the contract firm duration is USD 35.5 million, and the firm duration including options value is USD 49.3 million. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 17 September 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.9.2021 16:20:00 CEST | Press release

Bid procedure, 2021-09-23BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 520, SE0014694659, 2027-09-15 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-09-23Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 146: 700 mln SEK +/-350 mln SEK 581: 500 mln SEK +/-250 mln SEK 520: 600 mln SEK +/-300 mln SEK 2312: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 400 mln SEK per bid 1591: 1900 mln SEK per bid 146: 700 mln SEK per bid 581: 500 mln SEK per bid 520: 600 mln SEK per bid 2312: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 16:20:00 CEST | Press release

Bid procedure, 2021-09-24BondsSWEDISH GOVERNMENT: 1056. SE0004517290. 2032-06-01 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2021-09-24Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1056: 500 mln SEK +/-250 mln SEK 1053: 750 mln SEK +/-350 mln SEK Highest permitted bid volume (corresponding nominal amount)1056: 500 mln SEK per bid 1053: 750 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-09-28Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-09-17 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c